New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands

Pharmazie

Volumn 62, Issue 11, 2007, Pages 813-824

  Pasquinucci, Lorella ^a   Iadanza, M ^b   Marrazzo, A ^a   Prezzavento, O ^a   Ronsisvalle, S ^a   Scoto, G M ^a   Parenti, C ^a   De Luca, L ^c   Ronsisvalle, G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOMORPHAN DERIVATIVE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; TYROSINE;

ARTICLE; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS;

ANIMALS; BENZOMORPHANS; BRAIN; CYCLAZOCINE; GUINEA PIGS; INDICATORS AND REAGENTS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 36349021861     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2007.11.7523     Document Type: Article

References (33)

1. Bonnaud B, Cousse H, Mouzin G, Briley M, Stenger A, Fauran F, Couzinier JP (1987) 1-Aril-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants. J Med Chem 30: 318-325.
2. Brine GA, Berrang B, Hayes JP, Carroll FI (1990) An improved resolution of (±)-cis-N-Normetazocine. J Heterocycl Chem 27: 2139-2143.
3. Casadio S, Bonnaud B, Mouzin G, Cousse H (1978) Acide phenyl-1-hydroxymethyl-2-cyclopropane carboxylique et derives. Boll Chim Farm 117: 331-342.
4. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M (1996) International union of pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 48: 567-592.
5. Dosen-Micovic L, Ivanovic M, Micovic V (2006) Steric interactions and the activity of fentanyl analogs at the μ-opioid receptor. Bioorg Med Chem 14: 2887-2895.
6. Fujita Y, Tsuda Y, Li T, Motoyama T, Takahashi M, Shimizu Y, Yokoi T, Sasaki Y, Ambo A, Kita A, Jinsmaa Y, Bryant SD, Lazarus LH, Okada Y (2004) Development of potent bifunctional endomorphin-2 analogues with mixed μ-/δ-opioid agonist and δ-opioid antagonist properties. J Med Chem 47: 3591-3599.
7. Furness MS, Zhang X, Coop A, Jacobson AE, Rothman RB, Dersch CM, Xu H, Porreca F, Rice KC (2000) Probes for narcotic receptor-mediated phenomena. 27. Synthesis and pharmacological evaluation of selective δ-opioid receptor agonists from 4-[(αR)-α-(2S,5R)-4-substituted- 2,5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamides and their enantiomers. J Med Chem 43: 3193-3196.
8. Grieco P, Giusti L, Carotenuto A, Campiglia P, Calderone V, Lama T, Gomez-Monterrey I, Tartaro G, Mazzoni MR, Novellino E (2005) Morphiceptin analogues containing a dipeptide mimetic structure: an investigation on the bioactive topology at the μ-receptor. J Med Chem 48: 3153-3163.
9. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267: 727-748.
10. Kane BE, Nieto MJ, McCurdy CR, Ferguson DM (2006) A unique binding epitope for Salvinorin A, a non-nitrogenous kappa opioid receptor agonist. FEBS Journal 273: 1966-1974.
11. Kong H, Raynor K, Reisine T (1994) Amino acids in the cloned mouse kappa receptor that are necessary for high affinity agonist binding but not antagonist binding. Reg Pept 54: 155-156.
12. Kuhar MJ, Ritz MC, Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14: 299-302.
13. Lavecchia A, Greco G, Novellino E, Vittorio F, Ronsisvalle G (2000) Modeling of κ-opioid receptor/agonists interactions using pharmacophore-based and docking simulations. J Med Chem 43: 2124-2134.
14. Margolis EB, Hjelmstad GO, Bonci A, Fields HL (2003) κ-Opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci 23: 9981-9986.
15. Marrazzo A, Prezzavento O, Pappalardo MS, Bousquet E, Iadanza M, Pike VW, Ronsisvalle G (2002) Synthesis of (+)- and (-)-cis-2-[(1-adamantylamino) -methyl]-1-phenylcyclopropane derivatives as high affinity probes for σ1 and σ2 binding sites. Il Farmaco 57: 45-53.
16. McPherson GA (1985) Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods 14: 213-228.
17. Millan MJ (1990) κ-Opioid receptors and analgesia. Trends Pharmacol Sci 11: 70-76.
18. Neumeyer JL, Gu XH, van Vliet LA, DeNunzio NJ, Rusovici DE, Cohen DJ, Negus SS, Mello NK, Bidlack JM (2001) Mixed κ agonists and μ agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorg Med Chem Lett 11: 2735-2740.
19. Pogozheva ID, Przydzial MJ, Mosberg HI (2005) Homology modelling of opioid receptor-ligand complexes using experimental constraints. The AAPS Journal 7: E434-E448.
20. Prisinzano TE, Tidgewell K, Harding WW (2005) κ Opioids as potential treatments for stimulant dependence. AAPS Journal 7: E592-E599.
21. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T (1994) Pharmacological characterization of the cloned κ-, δ- and μ-opioid receptors. Mol Pharmacol 45: 330-334.
22. Ronsisvalle G, Pasquinucci L, Pappalardo MS, Vittorio F, Fronza G, Romagnoli C, Pistacchio E, Spampinato S, Ferri S (1993) Non-peptide ligands for opioid receptors. Design of κ-specific agonists. J Med Chem 36: 1860-1865.
23. 1 recognition sites. Life Sci 57: 1487-1495.
24. Ronsisvalle G, Marrazzo A, Prezzavento O, Pasquinucci L, Falcucci B, Di Toro R, Spampinato S (2000a) Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites. Bioorg Med Chem 8: 1503-1513.
25. Ronsisvalle G, Pasquinucci L, Pittalà V, Marrazzo A, Prezzavento O, Di Toro R, Falcucci B, Spampinato S (2000b) Nonpeptide analogues of dynorphin A(1-8): design, synthesis, and pharmacological evaluation of κ-selective agonists. J Med Chem 43: 2992-3004.
26. Ronsisvalle G, Marrazzo A, Pasquinucci L, Prezzavento O, Pappalardo MS, Vittorio F (2001) Specific κ opioid receptor agonists. Farmaco 56: 121-125 (Proceedings of the XVIth International Symposium on Medicinal Chemistry, Bologna, Italy, September 18-22, 2000).
27. Singh N, Chevé G, Ferguson DM, McCurdy CR (2006) A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist. J Comput Aided Mol Des 20: 471-493.
28. Shuto S, Ono S, Hase Y, Kamiyama N, Takada H, Yamasihita K, Matsuda A (1996) Conformational restriction by repulsion between adjacent substituents on a cyclopropane ring: design and enatioselective synthesis of 1-phenyl-2-(1-aminoalkyl)-N,N-diethylcyclopropanecarboxamides as potent NMDA receptor antagonist. J Org Chem 61: 915-923.
29. Surratt CK, Johnson PS, Moriwaki A, Seidleck BK, Blaschak CJ, Wang JB, Uhl GR (1994) μ Opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J Biol Chem 269: 20548-20553.
30. Tömböly C, Kövér KE, Péter A, Tourwé D, Biyashev D, Benyhe S, Borsodi A, Al-Khrasani M, Rónai AZ, Tóth G (2004) Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues. J Med Chem 47: 735-743.
31. Werling L, Frattali A, Portoghese PS, Takemori A, Cox B (1988) Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs. J Pharmacol Exp Ther 246: 282-286.
32. Yan F, Mosier PD, Westkaemper RB, Stewart J, Zjawiony JK, Vortherms TA, Sheffler DJ, Roth BL (2005) Identification of the molecular mechanisms by which the diterpenoid Salvinorin A binds to κ-opioid receptors. Biochemistry 44: 8643-8651.
33. Zhang A, Xiong W, Bidlack JM, Hilbert JE, Knapp BI, Wentland MP, Neumeyer JL (2004) 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed κ and μ opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors. J Med Chem 47: 165-174.